? R01 Newgard/Herman . Studies performed by our group have helped establish that branched-chain amino acids (BCAA) and related metabolites are associated with insulin resistance and T2D, predictive of diabetes development and intervention outcomes, and highly responsive to therapeutic interventions. The goal of this proposal is to fully understand the metabolic and molecular mechanisms linking concerted dysregulation of BCAA, glucose and lipid metabolism. Key recent findings leading to this proposal emerged when we altered branched-chain ketoacid dehydrogenase (BCKDH) complex activity via pharmacologic and molecular manipulation of its regulatory kinase (BDK) and phosphatase (PPM1K) in rodent models of obesity and metabolic disease. Treatment of Zucker-obese rats with BT2, a small molecule inhibitor of BDK, or a recombinant adenovirus expressing PPM1K lowered circulating BCAA and branched chain ketoacid levels, improved glucose tolerance and insulin sensitivity, and increased fatty acid oxidation while markedly decreasing liver triglycerides. Phosphoproteomics analysis revealed that in addition to their function to modify BCKDH activity, BDK and PPM1K also regulate the phosphorylation of the key lipogenic enzyme, ATP-citrate lyase (ACL). Whereas phosphorylation of BCKDH inhibits its activity, phosphorylation of ACL is an activating post-translational modification that leads to increased de novo lipogenesis. We also demonstrated that overnutrition or fructose feeding activates the carbohydrate sensing transcription factor, ChREBP, which upregulates both BDK and ACL expression while suppressing PPM1K. Altogether, these studies define a novel regulatory node integrating glucose, lipid, and BCAA metabolism that participates in the progression of metabolic disease. The current study seeks to understand the impact of chronic manipulation of the ChREBP/BDK/PPM1K regulatory node in multiple dietary contexts, and to expand our human studies to include evaluation of genetic and dietary variables, via the following specific aims: 1) To test the hypothesis that chronic hepatic BDK overexpression will exacerbate metabolic disease phenotypes; 2) To test the hypotheses that chronic hepatic PPM1K overexpression or ChREBP suppression will attenuate or prevent development of metabolic disease phenotypes; 3) To determine whether consumption of sugar-sweetened beverages (SSB) associates with circulating BCAA levels, and whether genetic variants in the ChREBP/BDK/PPM1K regulatory node interact with sugar consumption to regulate BCAA levels and other metabolic traits in human populations.

Public Health Relevance

? R01 Newgard/Herman . The goal of this project is to define mechanisms that link dysregulated branched chain amino acid, lipid and glucose metabolism in the pathogenesis of cardiometabolic diseases. Understanding these connections will likely lead to identification of new interventional targets for obesity-related diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK121710-01
Application #
9792043
Study Section
Integrative Physiology of Obesity and Diabetes Study Section (IPOD)
Program Officer
Castle, Arthur
Project Start
2019-08-19
Project End
2023-07-31
Budget Start
2019-08-19
Budget End
2020-07-31
Support Year
1
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Duke University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705